In vivo, the administration of PR-001573 significantly inhibited tumor growth with a TGI value of 100% and did not change the weight of hPD-L1-expressing colon cancer (MC38)-cell-grafted PD1- and CTLA4-transgenic female B6 mice [57]. This evidence concerns the gene PDCD1 and neoplasm.